Bayer has announced its intention to offload the Environmental Science Professional business as part of plans to accelerate the strategy implementation of its Crop Science division.
Irish CDMO ICON is to acquire US-based rival PRA Health Sciences in a cash-and-stock deal worth approximately $12 billion. Both boards of directors have unanimously approved the merger.
Another “Big Pharma” company with a stalled candidate of its own is stepping in to help boost national or regional Covid-19 vaccine supply. US president Joe Biden was due to announce on Mar. 2 that Merck & Co will help make the Johnson & Johnson single-shot vaccine that received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on Feb. 27.
In a deal due to close in the second half of this year, privately owned French salt producer Salins is buying Nouryon’s Salt Specialties business, including brands such as JOZO, NEZO, Suprasel, Sanal and KNZ, for an undisclosed sum. The Dutch company’s salt and chlor-alkali business belong to its Nobian arm.
Ineos Phenol and utility group Engie are planning a pilot project in Doel, Belgium, that will use hydrogen in a commercial-scale cogeneration plant, replacing the natural gas feed for generating electricity and heat. Initially, 10% of the gas feed will be replaced with hydrogen and, if all goes well, this will be increased to 20%. Engie is responsible for the design, installation and operation of the technology.
Charles River Laboratories has agreed to buy Cognate BioServices, a cell and gene therapy CDMO, for about $875 million. The purchase is expected to close by the end of March, subject to customary conditions and regulatory clearance.
Following a decline of 2% in 2020, European chemical production is forecast to pick up by 3% in 2021, before growth rates taper off slightly in 2022, but output in that year should still land 2% higher against 2021.
The US Food and Drug Administration (FDA) on 27 February granted an Emergency Use Authorization (EUA) to the Covid-19 vaccine developed by Janssen Biotech, part of US healthcare giant Johnson & Johnson’s pharmaceuticals arm. The “totality of the available data available data,” it said, provides “clear evidence” that the vaccine may be effective in preventing infection from the virus.
Shell has announced plans to produce sustainable aviation fuels together with UK-based ITM Power at its Rhineland refinery in Cologne-Wesseling, Germany. A new Bio-Power-to-Liquid plant would be the first such commercial plant ever, it said.
Arkema is planning to invest in more fluoropolymer capacity in China in order to meet strong demand into lithium-ion batteries, as well as the water filtration, construction coatings and semiconductor industries.
Germany’s Sirion Biotech has signed a license and collaboration agreement with major French pharma Sanofi on viral vector-based gene therapy. Financial terms of the agreement were not disclosed. The partners aim to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
For mRNA vaccine maker Moderna, March is gearing up to roar in like a lion, with the tailwind setting the pace for the year ahead. Reporting 2020 financial results on Feb. 25, the US biotech that before last year had not sold a single product said it expects to take in more than $18 billion in revenue from sales of Covid-19 vaccines during 2021.
Leading US gene therapy CDMO Catalent is buying all shares of another CDMO in the same field, plasmid DNA (pDNA) specialist’s Delphi Genetics, headquartered at Gosselie, Belgium. Concurrently, the New Jersey-based company is launching pDNA development and manufacturing services at its Rockville, Maryland, facility.
Vienna, Austria-based polyolefins and fertilizer producer Borealis plans to invest €17.6 million in a new Regenerative Thermal Oxidizer (RTO) for its polyolefins plants in Porvoo, Finland, as part of an effort to significantly lower the site’s CO2 emission.
Spanish engineering contractor Tecnicas Reunidas has signed a contract with Turkey’s Sasa Polyester to build a PTA plant. Located at Adana, Turkey, the plant will have a capacity of 1.5 million t/y. The value of the contract was not disclosed, although the total cost of the project is estimated by Sasa at $935 million.
Brazilian petchems and plastic group Braskem is spending $61 million to expand its production capacity for green ethylene, the sugarcane ethanol-derived main feedstock for renewable polyethylene, at its plant in Triunfo, Rio Grande do Sul, Brazil. With the expansion, expected to be completed in Q4 2022, capacity will rise from 200,000 t/y currently to 260,000 t/y.
Danish coatings manufacturer Hempel has agreed to buy Wattyl, an Australian and New Zealand producer of architectural and protective paints and coatings, from owner Sherwin-Williams. Financial terms of the transaction, which is expected to close by the end of March, were not disclosed.
On the same day that Sanofi and GSK announced the start of a new Phase 2 study of their delayed adjuvanted recombinant protein-based Covid-19 vaccine candidate, Sanofi disclosed it had signed an agreement to manufacture 12 million doses of Johnson & Johnson’s single-dose adenovirus-based Covid vaccine.
After completing the purchase of DuPont’s nutrition and biosciences unit, International Flavors & Fragrances (IFF) is looking to divest at least two of its expanded businesses, the Bloomberg news agency said, citing “people with knowledge of the matter.”
For the report "Value Creation in Chemicals 2020: Bouncing Back from a Year of Adversity", Boston Consulting Group (BCG) analyzed the development of the global chemicals market in the Covid-19 crisis in 2020 and in the years 2015 to 2019 using key figures. The result shows: The current crisis is forcing companies to increase their resilience. The entire value chain, exposure to the end industry, and technical, commercial and digital capabilities must be put to the test in order to respond more effectively to changes in the markets in the future.
Yara International has signed a Letter of Intent with Statkraft – Europe’s largest generator of renewable energy – and investment group Aker Horizons to establish a large-scale green ammonia plant in Norway. The partners plan to electrify and decarbonize Yara’s existing ammonia plant in Porsgrunn, targeting green hydrogen and green ammonia opportunities within shipping, agriculture and industrial applications.
The Belgian cities of Antwerp and Bruges have agreed to merge their respective ports, with the former taking an 80.2% share in the combined port and Bruges taking 19.8%. The merger remains subject to a number of conditions, including approval from Belgian competition authorities.
For several days, the Pfizer-BioNTech Covid-19 vaccine Comirnaty (BNT162b2) has dominated international headlines. From the market’s perspective, the most significant news is that the partners, as hinted earlier, have been able to reformulate the doses to facilitate storage at a higher temperature.
New US president Joe Biden has pledged to release altogether $4 billion in US funding to support Gavi, the global vaccine alliance. The president was expected to announce an initial $2 billion in funding at the virtual G-7 summit of the world’s largest economies on Feb. 19.
OMV and Kommunalkredit Austria – a bank specializing in infrastructure and energy financing – are investing in the construction of Austria’s largest electrolysis plant to produce green hydrogen. Total investment will be about €25 million, which will be split equally between both partners.
Sandoz, the generics division of Swiss drugmaker Novartis, is picking up GlaxoSmithKline’s cephalosporin antibiotics business, including the brands Zinnat, Zinacef and Fortum, for up to $500 million.
The IIoT continues to evolve, with countless solutions touting end-to-end process automation. However, one of the most important elements of IIoT — the human element — has taken a back burner in this hype cycle.
US-based CDMO Regis Technologies has completed a major expansion of its laboratory facilities for development of active pharmaceutical ingredients (APIs) at its site in Morton Grove, Illinois. The project, kicked off two years ago, doubles the company’s capacity to take on new development projects.
US biopharma AbbVie and compatriot biotech Caribou Biosciences have entered into a multi-year collaboration and license agreement to research and develop chimeric antigen receptor (CAR)-T cell therapeutics.
Spanish energy and petrochemical group Repsol has signed a licensing agreement for its propylene oxide/styrene monomer (PO/SM) and polyols technologies for three plants in China.
PolyPeptide Group has appointed Raymond De Vré as its new Chief Executive Officer (CEO). He will succeed Jane Salik who, after 15 years in this position, will concentrate on her role on the Board of Directors.
US chemical company Chemours announced on Feb. 11 that it had split its Fluoroproducts segment into two distinct businesses during the fourth quarter of 2020.
The World Health Organization (WHO) has granted emergency use authorization (EUA) to the AstraZeneca/ Oxford University coronavirus vaccine, in an attempt to distribute doses to more Third World countries. The vaccine will be produced by the Serum Institute of India and AstraZeneca-SKBio of South Korea.
As had been awaited, US healthcare giant Johnson & Johnson has applied to the European Medicines Authority (EMA) for conditional marketing authorization of its Covid-19 coronavirus vaccine throughout the EU.
Elkem, a Norwegian manufacturer of silicon-based advanced materials, has agreed to buy a brand-new production plant near Lyon in France. The identity of the seller was not disclosed but Elkem said the purchase price is in the low double-digit millions of euros.
